Detailed analysis of what kind of drug Seleniso (Silvio) is and its clinical application scope

Selinexor (trade name Xpovio) is an oral selective inhibitor of nuclear export (Selective Inhibitor of Nuclear Export, SINE). It specifically inhibits export protein 1 (XPO1/CRM1), preventing tumor suppressor proteins and regulatory proteins from being excreted from the nucleus, thereby restoring apoptosis signals and inhibiting cancer cell proliferation. Different from traditional chemotherapy, Selinisol is an anti-tumor drug with a unique targeting mechanism and can be effective in a variety of relapsed or refractory tumors.

Selinesol is currently mainly used to treat relapsed or refractory multiple myeloma (RRMM). In clinical trials, seliniso combined with low-dose dexamethasone (dexamethasone) showed significant efficacy, inducing considerable objective response rates (ORR) and disease control rates (DCR) even in patients who failed multiple lines of treatment. In addition, selinesol has been approved for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL), providing a new treatment option for these high-risk patients.

In addition to multiple myeloma and mantle cell lymphoma, selinesol is being studied clinically in multiple solid and hematological tumors, including relapsed acute myeloid leukemia (AML), triple-negative breast cancer (TNBC) and ovarian cancer. Early studies have shown that selinesol can enhance the efficacy of chemotherapy or immunotherapy in these tumors, providing new treatment possibilities for refractory patients. With further research in the future, its clinical application scope is expected to be further expanded.

Selinesol is an oral drug that is easy to use in outpatient clinics, but its adverse reactions need to be strictly managed. Common ones include: Nausea, vomiting, fatigue, thrombocytopenia and increased risk of infection. Patients should regularly monitor blood routine, liver and kidney function and electrolyte levels during use, and perform symptomatic treatment and dose adjustment under the guidance of a doctor. Reasonable combination regimen, standardized monitoring and individualized management can maximize the efficacy while reducing risks.

Reference link:https://www.drugs.com